Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
(Date:3/27/2015)... March 27, 2015 Earlier this year, ... promotion of hair regrowth in adult men and women ... or Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification ... plagued by products that over-promise and under-deliver, FDA Clearance ... faith and confidence among more than 80 million men ...
(Date:3/27/2015)... 2015  Neogen Corporation (NASDAQ: NEOG ) announced ... trading plan in accordance with Securities and Exchange Commission ... of Neogen Corporation, is a minority owner of this ... Herbert does not have control of this ... is only for a portion of the shares owned ...
(Date:3/27/2015)... Working in collaboration with the National ... London , Richmond Pharmacology is the first centre worldwide ... for an investigational RNAi therapeutic being developed for the treatment ... and heart. Read press release ... at St Georges University of London , ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Neogen CEO adopts 10b5-1 Trading Plan 2
... , , LA JOLLA, Calif., ... molecular diagnostics for the early detection of disease plus additional ... of a feasibility study using DermTech,s advanced EGIR(TM) technology to ... The two companies will now move forward with a proof-of-concept ...
... , CALGARY, July 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... that a poster presentation by Dr. Jacqueline Parker et ... in Combination with Temozolomide and Low Dose Irradiation in ... Therapy Alone" was made yesterday at the 28th American ...
... PRINCETON, N.J., July 15 BioWa, Inc. announced today that ... Darmstadt, Germany, providing the global healthcare and chemicals company with ... and commercialization of their antibody therapies with enhanced antibody-dependent cellular ... "We are extremely pleased about our partnership with Merck KGaA, ...
Cached Biology Technology:DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology 2DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology 3Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting 2BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA 2
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... researchers from 80 countries, the world,s scientists as well as ... Life, which provides the first in-depth look at the more ... of Marine Life initiative, started in 2000, is the result of ... of more than 540 expeditions and 9,000 days at sea, plus ...
... The new center is a continuum for the Center ... VTT in Finland. The center in So Paulo aims to ... American market. Important focus areas will be biomass, bioethanol, pulp ... R&D center in So Paulo is the fourth part in ...
... , Washington, D.C. (October 5, 2010) -- A prototype ... to non-invasively test drugs for their ability to kill ... The new device is built upon microfluidics -- a ... of fluids at the sub-millimeter scale -- and is ...
Cached Biology News:San Diego Supercomputer Center participates in first 'Census of Marine Life' 2Kemira and VTT to open a joint R&D center in Brazil 2Anti-tumor drugs tested by microfluidic device 2
... The mini incubation trays are ... to screen antigens that have ... Each tray has eight 10.5 ... that accommodate strips cut from ...
BD Falcon, microtest ELISA plate 96 well flat-bottom, clear. Polystyrene, nonsterile, no lid (25/sp, 100/ca) Packaging: 25 / pack, 100 / case ...
... process and you reduce the chance of ... CEQ 8000. Developed using Beckman Coulters extensive ... capillary electrophoresis technology, the CEQ 8000 is ... system automatically fills the capillary array with ...
... is a simple high performance method for ... detergents without significant dilution of protein solution. ... the Detergent-OUT Spin column and collect detergent ... for removing detergent from a maximum of ...
Biology Products: